Market Research Reports and Industry Reports

Cardiac Marker Diagnostic Testing Markets

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION

Cardiac marker diagnostic testing measures the concentration of certain proteins, i.e., biomarkers, which indicate the presence or severity of cardiovascular disease (CVD). Among the most prevalent CVDs are sudden cardiac arrest (SCA), acute myocardial infarction (AMI), congestive heart failure (CHF) and atherosclerosis. Every year, an estimated 17 million people worldwide die from a CVD. This TriMark Publications report describes the specific market segment of the in vitro diagnostics (IVD) market devoted to cardiac marker testing, including size; growth; industry trends; product development and investment; and clinical measurement devices, reagents and supplies.

Highly-attractive cardiac marker areas of growth covered in this review include: the cardiac rapid assay market, troponins, Creatine kinase-myocardial band (CK-MB) and brain natriuretic peptide (BNP) testing. Also examined are heart failure, myoglobin, homocysteine (Hcy), C-reactive protein (CRP), pulmonary embolism (PE) (D-dimer test), low-density and high-density lipoproteins (LDL and HDL), stroke, cardiac enzymes, albumin, cardiac markers used in clinical decisions, cardiac markers in renal failure, cardiac panels and point of care (POC) cardiac markers. This study also provides a thorough analysis of the companies known to be marketing, manufacturing or developing cardiac marker products in the U.S. and worldwide, as well as detailed tables, charts and figures covering the U.S., Europe and Asia markets.

1. Overview 7
1.1 Statement of Report 7
1.2 Objectives of This Report 7
1.3 Scope of This Report 9
1.4 Methodology 9
1.5 Executive Summary 10

2. Introduction 13
2.1 Global Diagnostic Products Industry 13
2.2 Barriers to Entry 17
2.3 Company Evaluation Overview 17
2.4 Market Outlook 18
2.5 Technologies and Products that are the Most Successful in the New IVD Environment 19

3. Cardiac Marker Testing Markets: Market Segment Analysis: Size, Growth and Share 20
3.1 Global Cardiac Marker Diagnostic Testing Markets 20
3.1.1 Clinical Utility of Cardiac Markers 25
3.1.2 Market Drivers in the Cardiac Marker Diagnostics Testing Sector 26
3.1.3 Market Restraints in Cardiac Marker Testing Segment 27
3.1.4 Principal Market Segments for Cardiac Marker Testing 27
3.1.5 Key Players in the Cardiac Marker Diagnostics Testing Segment 27
3.1.6 Cardiac Marker Testing Sector Analysis 28
3.2 U.S. Cardiac Marker Testing Market 29
3.2.1 Market Overview 29
3.2.2 Diagnostic Test Categories 30
3.2.3 U.S. Hospital POC Cardiac Markers 30
3.3 European Cardiac Marker Diagnostic Test Market 32
3.3.1 German Diagnostic Markets 34
3.3.2 U.K. Diagnostic Testing Market 36
3.3.2.1 U.K. Market Statistics 36
3.3.2.2 U.K. Competitive Analysis 37
3.3.2.3 U.K. Market Access 38
3.3.3 Italy 38
3.3.4 France 38
3.3.5 Spain 39
3.3.6 Belgium 39
3.3.7 Switzerland 39
3.3.8 Barriers to Entry to European Market 39
3.4 Japanese Diagnostic Testing Market 39
3.5 Chinese Diagnostic Testing Market 40
3.6 Canadian Diagnostic Market 43
3.7 Cardiac Marker Testing Individual Markets 43
3.7.1 Clinical Overview 43
3.7.2 Cardiac Acute Disease Markers 44
3.7.3 Market Overview 44
3.7.3.1 AMI and Troponins 47
3.7.3.2 Market Size and Growth Projections 50
3.7.3.3 Clinical Use of Cardiac Troponins 51
3.7.3.4 TnI and TnT Market Drivers 54
3.7.3.5 TnI and TnT Market Restraints 54
3.7.4 CK-MB and Cardiac Enzymes 55
3.7.4.1 CK Enzymes 55
3.7.4.2 Market Size and Growth Projections 56
3.7.4.3 CK-MB: Market Drivers 57
3.7.4.4 CK-MB: Market Restraints 57
3.7.5 Myoglobin 57
3.7.5.1 Market Size and Growth Projections 57
3.7.5.2 Clinical Use of Myoglobin 58
3.7.5.3 Myoglobin Market Drivers 59
3.7.5.4 Myoglobin Market Restraints 59
3.7.6 Natriuretic Peptides 59
3.7.6.1 Market Overview 59
3.7.6.2 Market Size and Growth Projections 61
3.7.6.3 Commercial Assays for BNP and NT-proBNP 61
3.7.6.4 Competitive Landscape 63
3.7.6.5 BNP Test Market Share 63
3.7.6.6 Clinical Applications of BNP/NT-proBNP 66
3.7.6.7 BNP NT-proBNP Market Drivers 69
3.7.6.8 BNP NT-proBNP Market Restraints 69
3.7.6.9 Future Projections and Trends of NP testing 69
3.7.7 Albumin 70
3.7.7.1 Intact Albumin 70
3.7.7.2 Albumin Cobalt Binding Test 70
3.7.7.3 Ischemic Modified Albumin 70
3.7.7.4 Microalbuminuria 72
3.7.8 Key Players in Cardiac Markers 73
3.7.9 Evaluation of Cardiac Markers 76
3.7.10 Cardiac Markers Use in Clinical Decisions 77
3.7.11 Status of Cardiac Markers in the ER 77
3.7.12 Cardiac Markers in Renal Failure 78
3.7.13 Troponins in Non-Ischemic Heart Disease 78
3.7.14 Market Restraints 79
3.7.15 Market Drivers 79
3.7.16 Cardiac Panels 79
3.7.17 POC Cardiac Markers 80
3.7.17.1 Market Size and Growth Rate 80
3.7.17.2 Market Restraints 81
3.7.17.3 The Next Wave 82

4. Cardiovascular Disease Markers 85
4.1 Cholesterol, HDL and LDL 85
4.1.1 Cholesterol Testing Market Forecasts 86
4.1.2 Cholesterol Market Growth Drivers 86
4.1.3 Market Outlook: U.S. Market Analysis 87
4.1.4 Trends and Issues 87
4.1.5 Key Players in the Cholesterol Kit Market 88
4.2 Homocysteine 88
4.3 Fibrinogen 88
4.4 C-Reactive Protein 88
4.5 Lipoprotein Fractions 90
4.6 Pulmonary Embolism (D-Dimer Test) 91
4.7 Oxidized LDL and HDL 92
4.8 Stroke 92

5. Cardiac Marker Testing Development Issues 93
5.1 Genetic Testing and Personalized Medicine 93
5.2 Preventive Medicine 93
5.3 Patient Safety and Quality Measures 93
5.4 Reimbursement 94
5.5 Cardiovascular 96
5.6 Screening for Diabetes 96
5.7 Other Reimbursement Concerns 97
5.7.1 Reimbursement for Routine Venipuncture 97
5.7.2 Japanese Reimbursements for Medical Devices 97
5.8 CPT Test Codes and Payment Amounts 97
5.9 Rapid Near-Patient Testing in Hospitals 98
5.10 Satellite Facilities 98
5.11 Regionalization of Laboratory Care 99
5.12 Requirements for POCT 100
5.12.1 Benefits of POCT 101
5.12.2 Turnaround Time for POCT 102
5.13 Clinical Laboratory Improvement Amendments (CLIA) 102
5.14 Regulatory Requirements 103
5.15 Record-keeping and Data Management 103
5.15.1 Effectiveness of Clinical Outcomes 103

6. Business Trends in the Industry 105
6.1 Sector Consolidation 105
6.2 Diagnostic Testing Growth Trends 105
6.3 Acquisition, License Agreements, Internal Development and Partnerships 107
6.4 Product Testing Depth in Cardiac Marker Testing 108
6.5 Government Regulation 108
6.5.1 U.S. Regulation 108
6.5.1.1 Importing Medical Devices into the U.S. 109
6.5.1.2 Exporting Medical Devices from the U.S. 110
6.5.2 U.K. Regulations 110
6.5.3 E.U. Regulations 112
6.5.4 Japanese Regulations 113
6.5.5 Chinese Regulations 113
6.6 Barriers to Growth 114
6.7 Drivers of Growth 114

7. Important Technology Trends 115
7.1 Trends in Cardiac Marker Diagnostic Testing 115
7.1.1 Fatty Acid Binding Protein 116
7.1.2 Glycogen Phosphorylase Isoenzyme BB 116
7.1.3 S-100 Protein 116
7.1.4 Cobalt-Binding Albumin 116
7.1.5 Myosin Light Chains 117
7.2 Cardiac Biomarker Research 117
7.2.1 Myeloperoxidase 117
7.2.2 Glutathione Peroxidase 117
7.2.3 Antioxidant Biomarkers 117
7.2.4 Oxidative Biomarkers 117
7.2.5 Inflammatory Biomarkers 119
7.2.6 Nitrosative Biomarkers 119
7.2.7 Hemostatic Biomarkers 120
7.3 Potential Stroke Markers 120
7.3.1 Pharmacogenomics: Cardiovascular Drugs and Proteomic Markers 120
7.3.2 Cardiac Proteomics 121
7.3.3 Drivers for Cardiovascular Proteomic Markers 121
7.3.4 Barriers to Cardiovascular Proteomic Markers 121
7.4 Future Developments for Cardiovascular Markers 121
7.5 Research Questions 122
7.5.1 Roches Biomarker Strategy 125
7.5.2 Biomarkers for Unstable Angina 125
7.6 Lp-PLA2 126
7.7 Urotensin 126

8. Company Profiles 127
8.1 Abbott Laboratories 127
8.2 Alere 130
8.3 Ani Biotech 131
8.4 Axis-Shield 131
8.5 Bayer Corporation 132
8.6 Beckman Coulter (now part of Danaher) 133
8.7 Biosite, Inc. (now a brand of Alere) 134
8.8 Johnson & Johnson 134
8.9 LifeSign 135
8.10 PreMD, Inc. 135
8.11 Randox Laboratories 135
8.12 Response Biomedical 136
8.13 Roche Diagnostics 136
8.14 Siemens Healthcare Diagnostics (f/k/a Bayer Healthcare Diagnostics, Diagnostic Products Corporation, and Dade Behring) 138
8.15 Sierra Resources International 139
8.16 Spectral Diagnostics, Inc. 139


List Of Tables

Table 2.1: World Population and Growth, 2000-2024 13
Table 2.2: Worldwide Market Share IVD Companies 14
Table 2.3: Global Clinical Laboratory Market Sales, 1998-2011 15
Table 2.4: U.S. In Vitro Central Lab Diagnostic Testing, 2003-2012 15
Table 2.5: Global Point of Care Revenues, 2005-2012 15
Table 3.1: Cardiac Marker Markets by Country, 2002-2010 20
Table 3.2: Total Global Cardiac Marker Market, 2002-2010 20
Table 3.3: Overall IVD Testing Market Worldwide, 2010 22
Table 3.4: Worldwide Distribution of IVD Testing, 2010 22
Table 3.5: Top 12 Countries for IVD Testing Markets, 2010 23
Table 3.6: Eight Largest Diagnostic Companies Worldwide, 2010 23
Table 3.7: Cardiac Markers 25
Table 3.8: Market Share of Cardiac Marker Segment 29
Table 3.9: U.S. Cardiac Marker Market, 2001-2010 29
Table 3.10: U.S. Cardiac Marker Diagnostic Testing Market Segments, 2010 30
Table 3.11: U.S. POC Cardiac Marker Sales, 2001-2010 31
Table 3.12: Cardiac Marker Market for Diagnostic Testing in Europe, 2001-2010 32
Table 3.13: Regional Comparison of Healthcare and IVD Expenditures 34
Table 3.14: German Diagnostics Products Market Sales, 1997-2008 35
Table 3.15: German Cardiac Marker Test Market, 2000-2010 35
Table 3.16: U.K. Cardiac Marker Market, 2001-2010 36
Table 3.17: Major U.K. IVD Manufacturers 37
Table 3.18: U.S. IVD Manufacturers Doing Business in the U.K. 37
Table 3.19: Other European Companies that Manufacture IVD Products in the U.K. 37
Table 3.20: Italian Cardiac Marker Market, 2001-2010 38
Table 3.21: French Cardiac Marker Market, 2001-2010 38
Table 3.22: Spanish Cardiac Marker Market, 2001-2010 39
Table 3.23: Japanese Cardiac Marker Diagnostic Testing Market, 2001-2010 40
Table 3.24: Chinese Diagnostics Products Market, 2000-2010 41
Table 3.25: Actual Reported Number of ER Visits in U.S. Hospitals, 1997-2010 46
Table 3.26: Common Causes of Chest Pain 46
Table 3.27: Rate of Inappropriate Discharge from the ER for Patients with AMI 47
Table 3.28: Continuing Analytical Issues for Implementation of Cardiac Troponin 49
Table 3.29: Global Cardiac Troponin Marker Market, 2001-2010 50
Table 3.30: U.S. Cardiac Troponin Marker Market, 2001-2010 51
Table 3.31: Trends in U.S. Sales of POC Cardiac Marker Tests, 1998-2010 51
Table 3.32: World Revenue from CK-MB Markets, 2001-2010 56
Table 3.33: U.S. Revenue from CK-MB Markets, 2001-2010 56
Table 3.34: World Myoglobin Market Revenues, 2001-2010 57
Table 3.35: U.S. Myoglobin Market Revenues, 2001-2010 58
Table 3.36: BNP Clinical Characteristics 60
Table 3.37: Worldwide Sales of BNP Diagnostic Tests, 2004-2010 61
Table 3.38: U.S. Sales of BNP Diagnostic Tests, 2004-2010 61
Table 3.39: Analytical Characteristics of Commercial BNP Assays per Manufacturer 63
Table 3.40: Analytical Characteristics of Commercial NT-proBNP Assays per Manufacturer 64
Table 3.41: Market Share of BNP Assays in the U.S. 65
Table 3.42: Market Share of NT-proBNP Assays in the U.S. 65
Table 3.43: U.S. Hospital Share Estimates of NP Usage 66
Table 4.1: HDL Levels in Adults 85
Table 4.2: LDL Levels in Adults 86
Table 4.3: LDL Screening Management Rates-Percent of Patient Population, 2004 86
Table 4.4: LDL Screening Management Rates-Percent of Patient Population, 2009 86
Table 4.5: Number of U.S. Cholesterol Tests, 2000-2010 87
Table 4.6: World CRP Market Revenue, 2001-2010 90
Table 4.7: U.S. CRP Market Revenue, 2001-2010 90
Table 4.8: Clinical Characteristics of D-Dimer 91
Table 5.1: POCT in Two Hospitals Cost Analysis with Labor Included 101
Table 5.2: Cost Analysis for Glucose Testing: POCT vs. Central Lab 101
Table 5.3: POCT Clinical Outcomes in AMI 104
Table 7.1: Oxidative Biomarker Research Assay Market Size 118
Table 7.2: Non-Lipid Markers of CVD 123
Table 8.1: Products Marketed by Abbott in the Diagnostic Market 129
Table 3.33: U.S. Revenue from CK-MB Markets, 2001-2010 55
Table 3.34: World Myoglobin Market Revenues, 2001-2010 56
Table 3.35: U.S. Myoglobin Market Revenues, 2001-2010 57
Table 3.36: BNP Clinical Characteristics 59
Table 3.37: Worldwide Sales of BNP Diagnostic Tests, 2004-2010 60
Table 3.38: U.S. Sales of BNP Diagnostic Tests, 2004-2010 60
Table 3.39: Commercial BNP Assays in the U.S. 63
Table 3.40: Market Share of BNP Assays in the U.S. 63
Table 3.41: Market Share of NT-proBNP Assays in the U.S. 63
Table 3.42: Siemens Healthcare Diagnostics Cardiac Marker Assays 77
Table 3.43: Cardiac Markers: Sampling Frequency 79
Table 3.44: Cardiac Marker Products by LifeSign 81
Table 4.1: HDL Levels in Adults 87
Table 4.2: LDL Levels in Adults 88
Table 4.3: LDL Screening Management Rates-Percent of Patient Population 88
Table 4.4: Number of U.S. Cholesterol Tests, 2000-2010 89
Table 4.5: World CRP Market Revenue, 2001-2010 91
Table 4.6: U.S. CRP Market Revenue, 2001-2010 92
Table 4.7: Clinical Characteristics of D-Dimer 93
Table 5.1: POCT in Two Hospitals Cost Analysis with Labor Included 103
Table 5.2: Cost Analysis for Glucose Testing: POCT vs. Central Lab 103
Table 5.3: Financial Comparison for Moderate and Waived CLIA Labs 104
Table 5.4: POCT Clinical Outcomes in AMI 106
Table 7.1: Oxidative Biomarker Research Assay Market Size 124
Table 7.2: Non-Lipid Markers of CVD 128
Table 8.1: Products Marketed by Abbott in the Diagnostic Market 136
Table 8.2: Products Marketed by Biosite in the Diagnostic Market 144


List Of Figures


Figure 2.1: Lab Industry Market Share 16
Figure 2.2: Market Share of Major Lab Testing Segments 16
Figure 3.1: Worldwide Distribution of IVD Testing, 2010 22


iCardiac Technologies, Inc Company Profile- Outlook, Business Segments, Competitors, Goods and Services, SWOT and Financial Analysis

iCardiac Technologies, Inc Company Profile is a complete analysis of the companys operations, strategies, outlook and historic performance. The research work analyzes key strategies in current market conditions, SWOT profile,

USD 200View Report

Global Fetal Cardiac Monitor Sales Market Report 2016

Notes:Sales, means the sales volume of Fetal Cardiac MonitorRevenue, means the sales value of Fetal Cardiac MonitorThis report studies sales (consumption) of Fetal Cardiac Monitor in Global market, especially in

USD 4000View Report

United States Cardiac Pacemakers Market Report 2016

Notes:Sales, means the sales volume of Cardiac PacemakersRevenue, means the sales value of Cardiac PacemakersThis report studies sales (consumption) of Cardiac Pacemakers in United States market, focuses on the top

USD 3800View Report

Cardiac Marker Testing Market - Global Forecast to 2021

Cardiac Marker Testing Market by Type (Troponin I & T, CK-MB, Myoglobin, BNP, hsCRP), Product (Reagent, Instrument), Method (Chemiluminescence, ELISA), Disease (Myocardial Infarction, Congestive Heart Failure), Testing (Lab, POC) -

USD 5650View Report

2016 Switzerland Tumor Marker Diagnostics Market: Emerging Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains—Test Volume and Sales Forecasts, Competitive Strategies, Opportunities

This new report from VPGMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends

USD 4850View Report

2016 Sweden Tumor Marker Diagnostics Market: Emerging Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains—Test Volume and Sales Forecasts, Competitive Strategies, Opportunities

This new report from VPGMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends

USD 4850View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 5500
  • 10 User Licence    $ 11000
  • Enterprise Wide Licence    $ 16500
$ 5500

Reports Details

Published Date : Aug 2016
No. of Pages :161
Country :Global
Category :Healthcare
Publisher :TriMark Publications, LLC
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment